RPI NET PROFIT CRASHES 36%, SALES RISE 13%

Article Abstract:

In 1997-98, Rhone-Poulenc India (RPI) recorded a 36 percent drop in net profit and 13 percent increase in sales. RPI was adversely affected by intense competition for two of its major pharma brands, Phensedyl and Stematil. (gsh) ------------------------------------------------------------ Financial Results: Rhone-Poulenc India (Rs in crore) ------------------------------------------------------------ Particulars 1997-98 1996-97 ------------------------------------------------------------ Sales 164.25 145.84 ------------------------------------------------------------ Other Income 7.86 10.41 ------------------------------------------------------------ Interest 0.36 0.22 ------------------------------------------------------------ Depreciation 3.14 3.06 ------------------------------------------------------------ Pre-Tax profit 19.36 31.47 ------------------------------------------------------------ Taxation 6.45 11.30 ------------------------------------------------------------ Net Profit 12.91 20.16 ------------------------------------------------------------ Dividend (%) 80.00 90.00 ------------------------------------------------------------

Comment:

Records 36% drop in net profit and 13% increase in sales in 1997-98

Rhone Poulenc India Ltd.

---

HMR REGISTERS 53% RISE IN NET

Article Abstract:

Hoechst Marion Roussel (HMR), a pharmaceuticals producer, made a net profit of Rs31.03 crore during 1997-98 (Rs20.26 crore in 1996-97). Its exports were Rs115 crore. It earned Rs10.74 crore from sale of fixed assets and development rights. The performance of HMR was affected by the ban on Baralgan. Between January-April 1998, HMR introduced four medicines. (ag) ------------------------------------------------------------ Financial performance of Hoechst Marion Roussel ------------------------------------------------------------ Particulars 1997-98 1996-97 (Rs in crore) ------------------------------------------------------------ Net sales 382.49 386.90 ------------------------------------------------------------ Interest 8.41 10.66 ------------------------------------------------------------ Depreciation 12.44 10.74 ------------------------------------------------------------ Extraordinary items 3.19 -7.6 ------------------------------------------------------------ Tax 14.23 14.86 ------------------------------------------------------------ Exports 115.00 - ------------------------------------------------------------

Comment:

Pharmaceuticals producer posts net profit of Rs31.03 crore in 1997-98 vs Rs20.26 crore in 1996-97

Hoechst Marion Roussel

---

WOCKHARDT Q1 SALES UP 32% TO Rs152.3 Cr

Article Abstract:

Wockhardt Ltd has achieved a sales turnover of Rs152.30 crore ($35.7 million) in the first quarter of current financial year, the three months ending September 30, 1998. This is an increase of 32 percent over Rs115.6 crore ($31.9 million) recorded in the first three months of 1997-98. In the first quarter, Workhardt launched three new specialised medical nutrition products for diabetes, renal failure, cancer, burns, trauma and TB. (uh)

Market information - general, Wockhardt Ltd.

Similar abstracts:

• Abstracts: SBI CAPS NET UP BY 63.4% IIBI POSTS 68% RISE IN NET DSP MERRILL LYNCH LEADS INVESTMENT BANKS LEAGUE
• Abstracts: SAIL IDLE UNITS TO FETCH Rs500 Cr. RINL POSTS 18% RISE IN SALES. SAIL'S NET PROFIT DOWN 65 PER CENT
• Abstracts: GINNI FILAMENTS LIMITED L&T POSTS 60% RISE IN Q3 PROFITS. L&T POWERS AHEAD WITH 29% RISE IN NET
• Abstracts: PARRY'S CONFECTIONERY NET UP 24 PER CENT NESTLE ON COURSE TO Rs1,800-Cr TURNOVER CADBURY NET TAKES 41% JUMP
• Abstracts: NOCIL DIVIDEND SLASHED FROM 25% TO 10% HLL MARKET CAP ZOOMS PAST Rs50,000-CR MARK. NOCIL NET DOWN 37%

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.